Philadelphia is a blossoming biotech cluster across a wide array of fields and market sectors. Cell and gene therapy is a rapidly growing sector; the area has a deep and diversified life sciences talent pool; medtech companies are thriving and are poised for even more growth; and a bevy of Philadelphia bioscience organizations have a focus on battling COVID-19 and preparing for the next infectious disease to threaten public health.
Chimeron Bio Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its RNA Oncology Candidates￼
Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, today announced it has entered into a manufacturing agreement with FUJIFILM Diosynth Biotechnologies (FDB), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies, to advance the Company’s Oncology portfolio to the clinic.
Philadelphia, the birthplace of cell and gene therapy, is home to a number of companies focused on developing multiple treatment options for rare diseases, those that affect less than 200,000 people in the United States.